- Title
- Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
- Creators
- Matthew Powell - Washington University in St. LouisAnnika Auranen - Tampere UniversityLyndsay Willmott - Arizona Cancer Care, Scottsdale, AZ, United StatesLucy Gilbert - McGill UniversityDestin Black - Louisiana State UniversityDavid Cibula - Charles UniversitySudarshan Sharma - Amita HealthGiorgio Valabrega - University of Torino, Torino, ItalyLisa Landrum - Indiana University HealthLars Hanker - University Hospital Schleswig-HolsteinAshley Stuckey - Providence CollegeIngrid Boere - Erasmus MCMichael Gold - Oklahoma Cancer Specialists and Research InstituteMark Shahin - Thomas Jefferson UniversityBhavana Pothuri - New York University Langone Health, New York, NY, United StatesBrian Slomovitz - University of MiamiMatthew Grimshaw - GSK, Waltham, MA, United StatesShadi Stevens - GSK, Waltham, MA, United StatesRobert Coleman - Sarah Cannon Research InstituteMansoor Mirza - Copenhagen University Hospital
- Publication Details
- Gynecologic oncology, Vol.190, pp.S4-S5
- Publisher
- Elsevier Inc
- Identifiers
- 991006118331902656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
Gynecologic oncology, Vol.190, pp.S4-S5
11/2024
Metrics
1 Record Views